Multiple Primary Melanoma Incidence Trends Over Five Decades: A Nationwide Population-Based Study.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
26
03
2020
revised:
12
05
2020
accepted:
09
06
2020
pubmed:
25
6
2020
medline:
30
9
2021
entrez:
25
6
2020
Statut:
ppublish
Résumé
Over the past decades, many regions have experienced a steady increase in the incidence of cutaneous melanoma. Here, we report on incidence trends for subsequent primary melanoma. In this nationwide population-based study, patients diagnosed with a first primary cutaneous melanoma reported to the Swedish Cancer Registry were followed for up to 10 years for a diagnosis of subsequent primary melanoma. Patients were grouped with patients diagnosed with first melanoma in the same decade (1960s, 1970s, 1980s, 1990s, and 2000s, respectively). Frequencies, incidence rates (IRs), standardized incidence ratios (SIRs), and 95% confidence intervals (CIs) for second melanomas were calculated. All tests of statistical significance were 2-sided. Of patients with melanoma, 54 884 were included and 2469 were diagnosed, within 10 years, with subsequent melanomas. Over the 5 decades, there was a statistically significant steady increase in the frequency, IR, and SIR for second primary melanoma. For example, in the 1960s cohort, less than 1% (IR = 1.0, 95% CI = 0.5 to 1.7, and IR = 1.1, 95% CI = 0.5 to 1.9 per 1000 person-years in women and men, respectively) had second primary melanoma, and this rose to 6.4% (IR = 7.5, 95% CI = 6.8 to 8.3, per 1000 person-years) in the women and 7.9% (IR = 10.3, 95% CI = 9.3 to 11.2, per 1000 person-years) in the men in the 2000s cohort. This rise was seen independent of age, sex, invasiveness, or site of the melanoma. Further, in patients diagnosed with a second melanoma, the frequency of those having more than 2 melanomas increased statistically significantly and was 0.0% in the 1960s and rose to 18.0% in the 2000s (P < .001). This is the first study to evaluate and report on a rising trend for subsequent primary melanoma. Additional primary melanomas worsen the patients' survival, and precautions are needed to turn this steep upgoing trend.
Sections du résumé
BACKGROUND
Over the past decades, many regions have experienced a steady increase in the incidence of cutaneous melanoma. Here, we report on incidence trends for subsequent primary melanoma.
METHODS
In this nationwide population-based study, patients diagnosed with a first primary cutaneous melanoma reported to the Swedish Cancer Registry were followed for up to 10 years for a diagnosis of subsequent primary melanoma. Patients were grouped with patients diagnosed with first melanoma in the same decade (1960s, 1970s, 1980s, 1990s, and 2000s, respectively). Frequencies, incidence rates (IRs), standardized incidence ratios (SIRs), and 95% confidence intervals (CIs) for second melanomas were calculated. All tests of statistical significance were 2-sided.
RESULTS
Of patients with melanoma, 54 884 were included and 2469 were diagnosed, within 10 years, with subsequent melanomas. Over the 5 decades, there was a statistically significant steady increase in the frequency, IR, and SIR for second primary melanoma. For example, in the 1960s cohort, less than 1% (IR = 1.0, 95% CI = 0.5 to 1.7, and IR = 1.1, 95% CI = 0.5 to 1.9 per 1000 person-years in women and men, respectively) had second primary melanoma, and this rose to 6.4% (IR = 7.5, 95% CI = 6.8 to 8.3, per 1000 person-years) in the women and 7.9% (IR = 10.3, 95% CI = 9.3 to 11.2, per 1000 person-years) in the men in the 2000s cohort. This rise was seen independent of age, sex, invasiveness, or site of the melanoma. Further, in patients diagnosed with a second melanoma, the frequency of those having more than 2 melanomas increased statistically significantly and was 0.0% in the 1960s and rose to 18.0% in the 2000s (P < .001).
CONCLUSIONS
This is the first study to evaluate and report on a rising trend for subsequent primary melanoma. Additional primary melanomas worsen the patients' survival, and precautions are needed to turn this steep upgoing trend.
Identifiants
pubmed: 32577730
pii: 5860838
doi: 10.1093/jnci/djaa088
pmc: PMC7936055
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
318-328Informations de copyright
© The Author(s) 2020. Published by Oxford University Press.
Références
J Natl Cancer Inst. 2002 Jun 19;94(12):894-903
pubmed: 12072543
Int J Cancer. 2018 Apr 15;142(8):1528-1535
pubmed: 29105744
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Acta Oncol. 2009;48(1):27-33
pubmed: 18767000
Br J Dermatol. 2014 Jan;170(1):11-9
pubmed: 23815297
Int J Cancer. 2009 Aug 15;125(4):909-17
pubmed: 19384953
Acta Oncol. 2010 Jun;49(5):665-72
pubmed: 20491525
Melanoma Res. 2020 Jun;30(3):247-251
pubmed: 31567591
Arch Dermatol. 2006 Apr;142(4):433-8
pubmed: 16618861
Int J Cancer. 2013 Jan 15;132(2):385-400
pubmed: 22532371
Eur J Cancer Prev. 2004 Apr;13(2):133-8
pubmed: 15100580
Lakartidningen. 2017 May 9;114:
pubmed: 28485768
Int J Cancer. 2001 Jun 15;92(6):883-7
pubmed: 11351311
J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S69-77
pubmed: 22018070
J Am Acad Dermatol. 2017 Nov;77(5):893-901
pubmed: 28818438
Cancer. 1983 Nov 1;52(9):1748-53
pubmed: 6616424
N Engl J Med. 1998 Mar 26;338(13):879-87
pubmed: 9516223
Nat Genet. 2014 May;46(5):482-6
pubmed: 24686846
Cancer Res. 2000 Dec 15;60(24):6864-7
pubmed: 11156381
Int J Mol Sci. 2013 Jun 07;14(6):12222-48
pubmed: 23749111
Int J Cancer. 2016 Aug 1;139(3):543-53
pubmed: 27004457
Science. 2013 Feb 22;339(6122):959-61
pubmed: 23348503
Int J Cancer. 2017 Dec 1;141(11):2243-2252
pubmed: 28799271
Nat Genet. 1996 Jan;12(1):97-9
pubmed: 8528263
J Am Acad Dermatol. 2015 Oct;73(4):630-6
pubmed: 26298295
J Invest Dermatol. 2016 Nov;136(11):2270-2276
pubmed: 27019458
Br J Dermatol. 2012 Dec;167(6):1321-30
pubmed: 22759226
Am Surg. 2010 Jul;76(7):675-81
pubmed: 20698369
Cancer Causes Control. 2008 Jun;19(5):451-8
pubmed: 18167620
Int J Cancer. 2015 Nov 1;137(9):2220-6
pubmed: 25943250
JAMA Dermatol. 2014 Aug;150(8):819-27
pubmed: 24964862
J Eur Acad Dermatol Venereol. 2015 Nov;29(11):2120-7
pubmed: 25864459
Eur J Cancer. 2018 Mar;92:108-118
pubmed: 29395684
J Med Genet. 2014 Aug;51(8):545-52
pubmed: 24935963
Pigment Cell Melanoma Res. 2009 Apr;22(2):196-204
pubmed: 19077144
J Natl Cancer Inst. 2014 Dec 13;107(2):
pubmed: 25505254
BMJ. 1994 Aug 6;309(6951):375
pubmed: 8081136
Int J Cancer. 2019 May 15;144(10):2453-2464
pubmed: 30414346
Int J Cancer. 2005 Dec 10;117(5):877-9
pubmed: 15957164
JAMA Dermatol. 2014 May;150(5):526-34
pubmed: 25093216
JAMA. 2016 Jul 26;316(4):436-47
pubmed: 27458949
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Nat Genet. 2014 May;46(5):478-481
pubmed: 24686849
J Clin Oncol. 2005 May 1;23(13):3043-51
pubmed: 15860862
Cancer Epidemiol Biomarkers Prev. 2006 Aug;15(8):1520-5
pubmed: 16896043
J Am Acad Dermatol. 2012 Jul;67(1):e17-27
pubmed: 21683472
Br J Dermatol. 2020 Aug;183(2):357-366
pubmed: 31794051
Int J Dermatol. 2007 Jun;46(6):575-7
pubmed: 17550554
JAMA. 2005 Oct 5;294(13):1647-54
pubmed: 16204664